doi: 10.1056/NEJMoa2022190 64 AnkerSDButlerJFilippatosGSJamalWSalsaliASchneeJet al
How GLP-1 dry mouth compares to other medication-induced dry mouth GLP-1 medications are far from the only drugs that cause dry mouth
Based on these results, semaglutide is expected to be submitted to FDA for MASH in 2025, potentially becoming the first GLP-1 RA officially approved for MASH
If the math is wrong, it gets caught before the vial is touched
With seven additional Phase 3 readouts expected in 2026, we believe retatrutide could become an important option for patients with significant weight loss needs and certain complications, including knee osteoarthritis." An investigational once-weekly triple hormone receptor agonist, retatrutide is a single molecule that activates the body's receptors for GIP, GLP-1, and glucagon
Want the gentle lane explained? Read our guide to microdosing semaglutide, or compare starting doses side by side in the GLP-1 microdosing dose chart